Your session is about to expire
← Back to Search
E7386 + Pembrolizumab for Solid Cancers
Study Summary
This trial is studying a combination of E7386 and pembrolizumab to see how well it works in treating patients with solid tumors that have been previously treated.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently being treated for an infection.I stopped a cancer treatment due to severe side effects.My brain metastases are stable, and I haven't needed steroids for 14 days.My cancer has worsened despite treatment.I have colorectal cancer and have had 2-4 treatments for it, but they didn't work or I couldn't tolerate them.I have been treated for an autoimmune disease in the last 2 years.I have an immune system disorder or have been on steroids or other immune-weakening drugs in the last week.I have had pneumonitis treated with steroids or have it now.I have a tumor that can be measured by CT or MRI.My blood tests show my organs are working well and my mineral levels are normal.I need medication or a procedure to remove fluid buildup in my body due to my condition.I have advanced melanoma not treatable by surgery and have had limited prior treatments.Participants with liver cancer must be in stage B or C and have only received one prior treatment for their advanced cancer. They must have progressed on treatment with a specific type of immunotherapy and meet certain blood pressure and vitamin D levels.My advanced cancer (melanoma, colorectal, or liver) has not responded to standard treatments.I am 18 years old or older.I am fully active or restricted in physically strenuous activity but can do light work.
- Group 1: Phase 2: E7386 + Pembrolizumab + Lenvatinib
- Group 2: Phase 1b and 2: E7386 + Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many volunteers have enrolled in this investigation?
"To execute the study, Merck Sharp & Dohme LLC requires 108 eligible patients. This trial is run from multiple sites including Florida Cancer Specialists in Fort Myers, Florida and SCRI Florida Cancer Specialists East in West Palm Beach, New jersey."
Is there still an opportunity to join this medical experiment?
"Affirmative. Clinicaltrials.gov provides evidence that this trial, which first appeared on October 27th 2021, is actively enrolling new candidates. A total of 108 participants need to be recruited from 8 different health institutions."
Have there been additional research initiatives regarding Pembrolizumab?
"Pembrolizumab was initially trialled at City of Hope in 2010 and has since undergone 252 completed studies. There are currently 961 active investigations, many of which are taking place in Fort Myers, Florida."
How many health centers are participating in this research initiative?
"At present, this medical venture is running out of 8 sites situated in Fort Myers, West Palm Beach and New Brunswick - as well as 5 other areas. It might be advantageous to pick a nearby site if you decide to join the trial; it'll reduce your travel needs."
To which conditions is Pembrolizumab frequently employed?
"Pembrolizumab is a viable treatment option for malignant neoplasms, unresectable melanoma, and cancers with high microsatellite instability."
Share this study with friends
Copy Link
Messenger